NPSA Highlights Risk Of Oral Anticancer Drugs
Country of origin: UK
Click for Full Details: www.npsa.nhs.ukAll healthcare staff need to monitor oral anticancer drugs to the same extent as injected anticancer drugs, according to a new report by the National Patient Safety Agency (NPSA). The NPSA received reports of three deaths and 400 patient safety incidents concerning oral anticancer drugs between November 2003 and July 2007.
The NPSA report suggests that all patients receive written information about their cancer treatment, along with contact details for obtaining specialist advice. It also suggests that healthcare staff responsible for prescribing, administering or dispensing oral anticancer medicines should have access to the written protocol and treatment plan from the hospital in which treatment was initiated.
Geoff Saunders, chairman of the British Oncology Pharmacy Association (BOPA), commented: ?Some cancer networks already have a good flow of information from the specialist hospitals. However, this does not happen everywhere, so some smaller hospitals will need to contact the local cancer network to ensure this information is passed on.?
The report asks for immediate action from all NHS care providers that prescribe, administer or dispense oral anticancer drugs, with action to be completed by 22 July 2008. BOPA expects to launch a toolkit in the next few weeks to help implement the changes.
Click for Full Details: www.npsa.nhs.uk
inPractice® Oncology July 2018
Cancer Research Network Measures March 2018
Orlive Surgical Broadcasts February 2018
Cancer.net mobile by ASCO January 2018
Chemo Calendar January 2018
Cancer Navigator January 2018
Oncology Nurse Advisor January 2018
Breast Cancer Survivor January 2018
Cancer Emergency Response Tool January 2018